Brief: Hansoh Pharmaceutical Says Units Entered Into A License Agreement With Regeneron Pharmaceuticals
02/06/2025 15:06
June 2 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: UNITS ENTERED INTO A LICENSE AGREEMENT WITH REGENERON PHARMACEUTICALS LICENSORS WILL RECEIVE AN UPFRONT PAYMENT OF US$80 MILLION AND BE ELIGIBLE TO RECEIVE UP TO US$1.93 BILLION IN MILESTONE PAYMENTS LICENSORS SHALL GRANT AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP, MANUFACTURE AND COMMERCIALIZE HS-20094 Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion